Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen on Clinical Outcome in Orthotopic Liver Transplant Recipients With Documented Gram-negative Infections

NCT06718517 is registered in ClinicalTrials.gov with IRCCS Azienda Ospedaliero-Universitaria di Bologna as lead sponsor.

NCT NCT06718517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06718517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen on Clinical Outcome in Orthotopic Liver Transplant Recipients With Documented Gram-negative Infections
Lead sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase
Observational
Overall status
Recruiting
Start date
August 28, 2024
Completion date
December 31, 2026
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver transplant infection